Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
- Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks - 88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of ≥5% and ≥10%, respectively - XW003 was safe and well tolerated, with an adverse event profile consistent with other GLP-1 analogs...
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 28, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication of YIKAIDA submitted by Fosun Kite Biotechnology Co., Ltd....
hemotune Applauded by Frost & Sullivan for Enabling Selective and Efficient Extraction of Large Compounds from Blood With Its Blood Purification Platform
HemoSystem improves patient outcomes while shortening the length of stay in intensive care units, reducing the sepsis burden for patients, hospitals, and healthcare systems. SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ -- Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award. The company developed a...
Life sciences industry’s highest achievers celebrated at prestigious Awards ceremony
AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO Company of the Year: Telix Pharmaceuticals Emerging Company of the Year: Fusetec AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO and Nicola Forrest AO PERTH, Australia, Oct, 27, 2022 /PRNewswire/ -- Biotech's illustrious Industry Excellence Awards were announced today at...
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challenges in the biotechnology industry, WuXi Biologics continues its growth momentum with multiple new early-phase and late-phase projects signed. The company...
Mentice Launches New Website
GOTHENBURG, Sweden, Oct. 27, 2022 /PRNewswire/ -- Mentice, a world leader in virtual and physical simulation solutions for Image-guided Interventional Therapies, is pleased to announce the launch of its new website www.mentice.com. Mentice is proud to present the platform's innovative design, structure, and content to the clinical and MedTech communities. The new website is designed to inspire and guide visitors...
The Evolution of U.S. Medical Tourism Virtual Summit: Insights and Perspectives
PALM BEACH GARDENS, Fla., Oct. 27, 2022 /PRNewswire/ -- Korea Tourism Organization and Global Healthcare Resources and the Medical Tourism Association have partnered to launch a private medical travel event for the American marketplace. Americans are looking beyond borders for solutions to their healthcare needs, leveraging medical travel opportunities to destinations that offer timely, quality and affordable healthcare services....
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment...
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne on 25...
Happiness Development Group Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement
NANPING, China, Oct. 27, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) announced today that on October 25, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement and the matter...
